Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APLT |
---|---|---|
09:32 ET | 198894 | 8.12 |
09:34 ET | 32013 | 8.265 |
09:36 ET | 37994 | 8.31 |
09:38 ET | 71927 | 8.1333 |
09:39 ET | 21305 | 8.0719 |
09:41 ET | 17454 | 8.06 |
09:43 ET | 8034 | 8.115 |
09:45 ET | 933 | 8.11 |
09:48 ET | 15128 | 8.0692 |
09:50 ET | 246328 | 8.0495 |
09:52 ET | 27294 | 8 |
09:54 ET | 19319 | 8 |
09:56 ET | 20360 | 7.98 |
09:57 ET | 9896 | 8.015 |
09:59 ET | 32762 | 7.97 |
10:01 ET | 4539 | 7.9983 |
10:03 ET | 17244 | 8.005 |
10:06 ET | 6738 | 7.99 |
10:08 ET | 7730 | 7.97 |
10:10 ET | 17617 | 7.995 |
10:12 ET | 5087 | 8.005 |
10:14 ET | 5573 | 8.09 |
10:15 ET | 76016 | 7.995 |
10:17 ET | 38635 | 7.9992 |
10:19 ET | 30371 | 8 |
10:21 ET | 27121 | 8.01 |
10:24 ET | 18415 | 7.995 |
10:26 ET | 7706 | 8.005 |
10:28 ET | 69842 | 8.03 |
10:30 ET | 18817 | 7.995 |
10:32 ET | 41465 | 8 |
10:33 ET | 16320 | 8.005 |
10:35 ET | 21695 | 7.995 |
10:37 ET | 9773 | 8 |
10:39 ET | 30316 | 8.01 |
10:42 ET | 38833 | 7.995 |
10:44 ET | 229994 | 7.985 |
10:46 ET | 39053 | 7.99 |
10:48 ET | 9258 | 7.985 |
10:50 ET | 6280 | 7.995 |
10:51 ET | 14177 | 7.985 |
10:53 ET | 2911 | 7.985 |
10:55 ET | 3881 | 7.985 |
10:57 ET | 3600 | 7.995 |
11:00 ET | 49410 | 8 |
11:02 ET | 11118 | 7.98 |
11:04 ET | 19262 | 7.997502 |
11:06 ET | 21111 | 7.995 |
11:08 ET | 2000 | 8 |
11:09 ET | 2778 | 7.995 |
11:11 ET | 3300 | 7.995 |
11:13 ET | 32313 | 7.912 |
11:15 ET | 9823 | 7.94 |
11:18 ET | 13364 | 7.93 |
11:20 ET | 3976 | 7.955 |
11:22 ET | 1500 | 7.955 |
11:24 ET | 1340 | 7.955 |
11:26 ET | 21644 | 7.95 |
11:27 ET | 1640 | 7.95 |
11:29 ET | 11016 | 7.915 |
11:31 ET | 25753 | 7.88 |
11:33 ET | 18132 | 7.87 |
11:36 ET | 45508 | 7.82 |
11:38 ET | 12654 | 7.822 |
11:40 ET | 1958 | 7.845 |
11:42 ET | 5727 | 7.825 |
11:44 ET | 4707 | 7.8425 |
11:45 ET | 5641 | 7.87 |
11:47 ET | 3022 | 7.8625 |
11:49 ET | 3580 | 7.855 |
11:51 ET | 21333 | 7.79 |
11:54 ET | 21998 | 7.75 |
11:56 ET | 12972 | 7.76 |
11:58 ET | 15648 | 7.7 |
12:00 ET | 28147 | 7.69 |
12:02 ET | 27842 | 7.64 |
12:03 ET | 79682 | 7.56 |
12:05 ET | 24595 | 7.66 |
12:07 ET | 23413 | 7.685 |
12:09 ET | 4384 | 7.65 |
12:12 ET | 17258 | 7.63 |
12:14 ET | 24469 | 7.61 |
12:16 ET | 5059 | 7.61 |
12:18 ET | 5063 | 7.59 |
12:20 ET | 7925 | 7.63 |
12:21 ET | 1600 | 7.625 |
12:23 ET | 26657 | 7.65 |
12:25 ET | 9847 | 7.61 |
12:27 ET | 18672 | 7.735 |
12:30 ET | 7877 | 7.76 |
12:32 ET | 6095 | 7.77 |
12:34 ET | 16088 | 7.71 |
12:36 ET | 27250 | 7.77 |
12:38 ET | 8567 | 7.78 |
12:39 ET | 1300 | 7.78 |
12:41 ET | 6226 | 7.78 |
12:43 ET | 4668 | 7.755 |
12:45 ET | 2510 | 7.74 |
12:48 ET | 3201 | 7.825 |
12:50 ET | 7254 | 7.79 |
12:52 ET | 2400 | 7.81 |
12:54 ET | 3205 | 7.83 |
12:56 ET | 2847 | 7.84 |
12:57 ET | 3277 | 7.85 |
12:59 ET | 14213 | 7.79 |
01:01 ET | 8771 | 7.8 |
01:03 ET | 19716 | 7.79 |
01:06 ET | 1313 | 7.79 |
01:08 ET | 2800 | 7.81 |
01:10 ET | 3851 | 7.85 |
01:12 ET | 600 | 7.85 |
01:14 ET | 6872 | 7.83 |
01:15 ET | 3743 | 7.81 |
01:17 ET | 7160 | 7.75 |
01:19 ET | 1358 | 7.74 |
01:21 ET | 8064 | 7.73 |
01:24 ET | 11749 | 7.69 |
01:26 ET | 11133 | 7.69 |
01:28 ET | 13137 | 7.73 |
01:30 ET | 4561 | 7.72 |
01:32 ET | 3918 | 7.78 |
01:33 ET | 2352 | 7.79 |
01:35 ET | 5433 | 7.83 |
01:37 ET | 4219 | 7.82 |
01:39 ET | 900 | 7.82 |
01:42 ET | 5513 | 7.85 |
01:44 ET | 8586 | 7.87 |
01:46 ET | 4390 | 7.89 |
01:48 ET | 7101 | 7.87 |
01:50 ET | 8880 | 7.89 |
01:51 ET | 3700 | 7.94 |
01:53 ET | 4450 | 7.94 |
01:55 ET | 4687 | 7.935 |
01:57 ET | 14678 | 7.9 |
02:00 ET | 3952 | 7.91 |
02:02 ET | 24614 | 7.91 |
02:04 ET | 30110 | 7.91 |
02:06 ET | 5452 | 7.92 |
02:08 ET | 2819 | 7.915 |
02:09 ET | 6220 | 7.87 |
02:11 ET | 5348 | 7.92 |
02:13 ET | 9489 | 7.99 |
02:15 ET | 8133 | 7.96 |
02:18 ET | 8519 | 7.95 |
02:20 ET | 8892 | 7.905 |
02:22 ET | 10658 | 7.95 |
02:24 ET | 8917 | 7.955 |
02:26 ET | 13964 | 7.96 |
02:27 ET | 3814 | 7.97 |
02:29 ET | 13323 | 7.93 |
02:31 ET | 6340 | 7.93 |
02:33 ET | 3824 | 7.94 |
02:36 ET | 3250 | 7.95 |
02:38 ET | 20617 | 7.97 |
02:40 ET | 7632 | 7.97 |
02:42 ET | 7868 | 7.98 |
02:44 ET | 44929 | 8.04 |
02:45 ET | 15113 | 7.98 |
02:47 ET | 5544 | 7.985 |
02:49 ET | 61375 | 8 |
02:51 ET | 14088 | 7.9976 |
02:54 ET | 4068 | 7.9854 |
02:56 ET | 4557 | 7.995 |
02:58 ET | 8363 | 7.975 |
03:00 ET | 3879 | 7.99 |
03:02 ET | 9750 | 7.985 |
03:03 ET | 14303 | 7.945 |
03:05 ET | 13963 | 7.955 |
03:07 ET | 16787 | 7.93 |
03:09 ET | 7509 | 7.92 |
03:12 ET | 13508 | 7.91 |
03:14 ET | 3303 | 7.93 |
03:16 ET | 8406 | 7.935 |
03:18 ET | 21761 | 7.87 |
03:20 ET | 9712 | 7.895 |
03:21 ET | 8276 | 7.89 |
03:23 ET | 10849 | 7.895 |
03:25 ET | 11741 | 7.89 |
03:27 ET | 11048 | 7.9 |
03:30 ET | 10520 | 7.915 |
03:32 ET | 12048 | 7.925 |
03:34 ET | 15095 | 7.93 |
03:36 ET | 7138 | 7.905 |
03:38 ET | 12038 | 7.905 |
03:39 ET | 16418 | 7.89 |
03:41 ET | 18368 | 7.89 |
03:43 ET | 57524 | 7.83 |
03:45 ET | 28497 | 7.8001 |
03:48 ET | 34649 | 7.795 |
03:50 ET | 26285 | 7.8456 |
03:52 ET | 127225 | 7.8 |
03:54 ET | 37133 | 7.785 |
03:56 ET | 98548 | 7.79 |
03:57 ET | 70681 | 7.71 |
03:59 ET | 3532522 | 7.7 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Applied Therapeutics Inc | 884.3M | -5.1x | --- |
Immunome Inc | 900.2M | -2.7x | --- |
Mereo BioPharma Group PLC | 653.9M | -12.9x | --- |
Perspective Therapeutics Inc | 892.1M | -9.5x | --- |
Oruka Therapeutics Inc | 875.0M | -4.2x | --- |
89Bio Inc | 867.4M | -4.2x | --- |
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $884.3M |
---|---|
Revenue (TTM) | $-333.0K |
Shares Outstanding | 114.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.03 |
EPS | $-1.52 |
Book Value | $-0.20 |
P/E Ratio | -5.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.